{"id":33967,"date":"2025-05-23T01:03:15","date_gmt":"2025-05-22T17:03:15","guid":{"rendered":"https:\/\/flcube.com\/?p=33967"},"modified":"2025-05-23T01:03:16","modified_gmt":"2025-05-22T17:03:16","slug":"bayer-launches-phase-i-study-of-bay-3670549-for-atrial-fibrillation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33967","title":{"rendered":"Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation"},"content":{"rendered":"\n<p>German pharmaceutical giant Bayer (<a href=\"https:\/\/www.google.com\/finance\/quote\/BAYN:ETR\">ETR: BAYN<\/a>) this week initiated a Phase I clinical study for its BAY 3670549, a G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor. The drug is designed to help control the electrical activity of heart cells in patients with atrial fibrillation (AFib). This investigative approach aims to enable rapid cardioversion to normal sinus rhythm, allowing immediate treatment without the need for anesthesia\/sedation and electrical shock, and significantly reducing patients&#8217; time spent in hospital.<\/p>\n\n\n\n<p><strong>Mechanism of Action<\/strong><br>GIRK4 channels are specialized proteins that regulate the electrical activity of heart cells by facilitating the flow of potassium ions (K+) in response to the neurotransmitter acetylcholine (ACh). This mechanism is particularly crucial during the later phases of the heart\u2019s electrical signaling, specifically during the atrial effective refractory period (AERP). Increased activity of these channels shortens the AERP in the atria (the upper chambers of the heart), thereby reducing the recovery time after each heartbeat. This alteration in recovery time can contribute to the onset and persistence of AFib.<\/p>\n\n\n\n<p><strong>Clinical Trial Objectives<\/strong><br>The Phase I study of BAY 3670549 will assess the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers. The ultimate goal is to develop a treatment that can rapidly restore normal heart rhythm in patients with AFib, improving clinical outcomes and patient quality of life.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>German pharmaceutical giant Bayer (ETR: BAYN) this week initiated a Phase I clinical study for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33968,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[269,62,69,967],"class_list":["post-33967","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-bayer","tag-clinical-trial-approval-initiation","tag-cvd","tag-etr-bayn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"German pharmaceutical giant Bayer (ETR: BAYN) this week initiated a Phase I clinical study for its BAY 3670549, a G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor. The drug is designed to help control the electrical activity of heart cells in patients with atrial fibrillation (AFib). This investigative approach aims to enable rapid cardioversion to normal sinus rhythm, allowing immediate treatment without the need for anesthesia\/sedation and electrical shock, and significantly reducing patients&#039; time spent in hospital.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33967\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation\" \/>\n<meta property=\"og:description\" content=\"German pharmaceutical giant Bayer (ETR: BAYN) this week initiated a Phase I clinical study for its BAY 3670549, a G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor. The drug is designed to help control the electrical activity of heart cells in patients with atrial fibrillation (AFib). This investigative approach aims to enable rapid cardioversion to normal sinus rhythm, allowing immediate treatment without the need for anesthesia\/sedation and electrical shock, and significantly reducing patients&#039; time spent in hospital.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33967\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-22T17:03:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-22T17:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2516.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33967#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33967\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation\",\"datePublished\":\"2025-05-22T17:03:15+00:00\",\"dateModified\":\"2025-05-22T17:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33967\"},\"wordCount\":232,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33967#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2516.webp\",\"keywords\":[\"Bayer\",\"Clinical trial approval \\\/ initiation\",\"CVD\",\"ETR: BAYN\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33967#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33967\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33967\",\"name\":\"Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33967#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33967#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2516.webp\",\"datePublished\":\"2025-05-22T17:03:15+00:00\",\"dateModified\":\"2025-05-22T17:03:16+00:00\",\"description\":\"German pharmaceutical giant Bayer (ETR: BAYN) this week initiated a Phase I clinical study for its BAY 3670549, a G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor. The drug is designed to help control the electrical activity of heart cells in patients with atrial fibrillation (AFib). This investigative approach aims to enable rapid cardioversion to normal sinus rhythm, allowing immediate treatment without the need for anesthesia\\\/sedation and electrical shock, and significantly reducing patients' time spent in hospital.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33967#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33967\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33967#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2516.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2516.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33967#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation - Insight, China&#039;s Pharmaceutical Industry","description":"German pharmaceutical giant Bayer (ETR: BAYN) this week initiated a Phase I clinical study for its BAY 3670549, a G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor. The drug is designed to help control the electrical activity of heart cells in patients with atrial fibrillation (AFib). This investigative approach aims to enable rapid cardioversion to normal sinus rhythm, allowing immediate treatment without the need for anesthesia\/sedation and electrical shock, and significantly reducing patients' time spent in hospital.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33967","og_locale":"en_US","og_type":"article","og_title":"Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation","og_description":"German pharmaceutical giant Bayer (ETR: BAYN) this week initiated a Phase I clinical study for its BAY 3670549, a G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor. The drug is designed to help control the electrical activity of heart cells in patients with atrial fibrillation (AFib). This investigative approach aims to enable rapid cardioversion to normal sinus rhythm, allowing immediate treatment without the need for anesthesia\/sedation and electrical shock, and significantly reducing patients' time spent in hospital.","og_url":"https:\/\/flcube.com\/?p=33967","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-22T17:03:15+00:00","article_modified_time":"2025-05-22T17:03:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2516.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33967#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33967"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation","datePublished":"2025-05-22T17:03:15+00:00","dateModified":"2025-05-22T17:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33967"},"wordCount":232,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33967#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2516.webp","keywords":["Bayer","Clinical trial approval \/ initiation","CVD","ETR: BAYN"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33967#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33967","url":"https:\/\/flcube.com\/?p=33967","name":"Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33967#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33967#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2516.webp","datePublished":"2025-05-22T17:03:15+00:00","dateModified":"2025-05-22T17:03:16+00:00","description":"German pharmaceutical giant Bayer (ETR: BAYN) this week initiated a Phase I clinical study for its BAY 3670549, a G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor. The drug is designed to help control the electrical activity of heart cells in patients with atrial fibrillation (AFib). This investigative approach aims to enable rapid cardioversion to normal sinus rhythm, allowing immediate treatment without the need for anesthesia\/sedation and electrical shock, and significantly reducing patients' time spent in hospital.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33967#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33967"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33967#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2516.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2516.webp","width":1080,"height":608,"caption":"Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33967#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2516.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33967","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33967"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33967\/revisions"}],"predecessor-version":[{"id":33969,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33967\/revisions\/33969"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33968"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33967"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33967"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33967"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}